Calithera Biosciences, Inc. (NASDAQ:CALA) gapped down prior to trading on Tuesday . The stock had previously closed at $16.85, but opened at $16.45. Calithera Biosciences shares last traded at $11.72, with a volume of 2855900 shares trading hands.
A number of research firms recently commented on CALA. BidaskClub lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Monday, November 6th. Finally, William Blair began coverage on Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Calithera Biosciences currently has an average rating of “Buy” and a consensus price target of $15.17.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.02 million. equities analysts predict that Calithera Biosciences, Inc. will post -0.77 EPS for the current year.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the company’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.30% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC grew its stake in shares of Calithera Biosciences by 10.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock worth $222,000 after acquiring an additional 1,472 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Calithera Biosciences by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 4,863 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Calithera Biosciences by 68.1% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 17,000 shares of the biotechnology company’s stock worth $252,000 after acquiring an additional 6,885 shares during the period. Wells Fargo & Company MN grew its stake in shares of Calithera Biosciences by 25.8% during the 3rd quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 6,910 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Calithera Biosciences during the 2nd quarter worth $120,000. Institutional investors own 71.88% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://transcriptdaily.com/2017/11/15/calithera-biosciences-inc-cala-shares-gap-down-to-16-45.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.